BCAB BCAB
Company Profile ↓Company Overview
BCAB (BCAB) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -79.97% |
| 6 Months: | -64.81% |
| 3 Months: | -24.09% |
| 1 Month: | -18.50% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 94.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 300.00K | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - |
| Operating Income | -1.11M | -4.52M | -8.02M | -18.80M | -30.46M | -23.70M | -24.35M | -29.05M | -26.18M | -28.93M | -37.20M | -35.02M | -24.46M | -21.97M | -11.27M | -17.61M | -18.65M | -13.79M | -9.31M |
| Net Income | -1.60M | -6.22M | -11.63M | -18.70M | -30.38M | -22.93M | -24.25M | -28.91M | -25.78M | -27.46M | -35.75M | -33.33M | -23.23M | -21.07M | -10.59M | -15.33M | -18.71M | -15.78M | -6.34M |
| Diluted EPS | - | - | - | - | -0.90 | -0.68 | -0.65 | -0.77 | -0.69 | -0.58 | -0.75 | -0.70 | -0.48 | -0.44 | -0.22 | -13.16 | -0.32 | -0.27 | -4.22 |
| R&D Expense | 1.66M | 2.92M | 4.86M | 10.42M | 14.85M | 16.55M | 16.92M | 20.71M | 19.84M | 21.70M | 30.96M | 28.40M | 18.85M | 16.20M | 16.39M | 12.36M | 13.68M | 9.54M | 4.58M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 300.00K | - | - | - | - |
| Operating Income | -28.27M | -30.10M | -96.44M | -108.14M | -129.69M | -73.94M | -59.30M |
| Net Income | -29.86M | -35.85M | -95.40M | -106.48M | -123.46M | -69.78M | -59.61M |
| Diluted EPS | - | - | -2.76 | -2.74 | -2.58 | -1.44 | -1.01 |
| R&D Expense | 25.92M | 19.93M | 58.27M | 79.35M | 103.73M | 63.09M | 43.57M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 244.94M | 254.42M | 225.74M | 119.66M | 52.42M | 13.83M |
| Total Equity | -28.45M | -56.01M | 209.97M | 210.82M | 180.34M | 70.67M | 14.27M | -36.19M |
| Cash & Equivalents | 10.86M | 3.70M | 238.60M | 244.98M | 215.51M | 111.47M | 49.05M | 7.12M |
| Total Liabilities | - | - | 34.96M | 43.60M | 45.40M | 48.99M | 38.16M | 50.02M |
| Current Liabilities | - | - | 32.26M | 19.81M | 23.13M | 28.34M | 14.54M | 21.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.64M | -36.33M | -62.21M | -90.42M | -104.02M | -71.94M | -48.20M |
| Investing Cash Flow | -1.51M | -590.00K | -924.00K | -265.00K | -98.00K | 0 | - |
| Financing Cash Flow | 4.00M | 271.82M | 69.51M | 61.21M | 77.00K | 9.51M | 6.28M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -32,146.7% | - | - | - | - |
| Net Margin % | - | - | -31,800.7% | - | - | - | - |
| ROE % | 53.3% | -17.1% | -45.3% | -59.0% | -174.7% | -489.1% | 164.7% |
| ROCE % | - | -14.2% | -41.1% | -53.4% | -142.0% | -195.2% | 732.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BCAB
BioAtla shrinks share count 50-for-1 to meet Nasdaq's $1 bid rule - Stock Titan
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxPRkVwbzJaT2Z3Q2dGbDl2MUU0U0RtcmhBZWNuNjFKS3Y4T2Z1YXlIOVdESUtRTlVvVE4tVTJqVVJKY3U2YS1qQXVMaTlUSUZyLWZpajZRVXB1U2o4SWFkN1VSM3QzNmNPVGw5RTYyN2NvOUw2N0JqOEJ6c0wtU0p4cmxfTVAzZw?oc=5" t…
BCAB|Bioatla Inc|Price:3.300|Chg%:+0.010 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5kdDRMck5FNTU1aVVoZEZyNHZpclZQWmdoWGo4ZGdobHB2bE9HR2pnalVaTloyMFk3SWNJMXUtRHlzQTZXczRNRjJua3dNZFN2ZTZwZlpVWEhXb3VOZm44OXdORGtDMzAtNkgxaWF3?oc=5" target="_blank">BCAB|Bioatla Inc|Pr…
BioAtla Announces Share Consolidation - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPUUhNWmVwOERTbTFJRWo0dnVQUno1MGxseGdLRkJidVFDYlVkajZxRmpiM0I5WjFnYlpiMV9iVkVMcHNIMmdPdjYzeFE5Z1JJdnJoZ0dQbUQyQ1h0RWFYbl9maW00OF9raEdWTzhGNjFIZDlwZGVqWjQ0MVBFaTktbFFmYjEyTmlKd0xTNH…
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxNTkI2NlVjaGVxaVd1N2I2THZhTHBIRjI4UmVYMkRid3gzenFqRWs0aWhHczBndUpJN1JTX2NrYjgxV3FyNzNzTGI1NjJfVTZCZU1ycW1UeWRYZUpEZFpDTTAtQWM5RXY1NG8xX05obEdwSUdhVS1XR3dJc3VQQUkzaV9YN3ZkU2N6VHYzaE…
BioAtla to be suspended from Nasdaq after delisting determination - Investing.com
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQZ3BwMDgyNkgtTk5MVUxLOElyQnYxcE1CM2ZpLWQzLU5SeW90Tlp5TzE4aXhIbEhDbS1DdjYzekJJU1llTUJVaHZYc3FneDJqZkphc2s5d240MGNzLVNXYS0yTFkzdV94dVA0MFNjX3M5QVdvWktiWUtmc3FsOE1Ma1pVd1hVdk1FSlRXSE…
BCAB Q4 2025 Earnings: Narrowing Losses Beat Street Estimates as Stock Rises 4% - Annual Financial Report - po-news-eg.net
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPb1pIaTJ2d2JBa2UydV9SSDhHTFNUYTlSQTZYVC1DZE45RGtOZWthWkd2MHdsUi1PZGNJNmhMTlJPc1ZVbW9MM20wTTJ2Sl9iVnhlNjlXNTNBQWYxdkYxZGQzT2taSFdDVE40Q3Vib043anJKN0o2XzV2TFBldWNSUVZQTzlVZHYyRXRTSE…
BCAB — Frequently Asked Questions
What is the current share price of BCAB?
As of 2026-08-05 17:25 PDT, BCAB trades at $3.32 on NASDAQ/NYSE. Its 52-week range is $3.22 to $61.00.
What is the P/E ratio of BCAB?
BCAB trades at a trailing price-to-earnings (P/E) ratio of -3.29.
Is BCAB a good stock to buy?
This page provides a data-driven analysis of BCAB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.